UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in BioNTech SE (NASDAQ:BNTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 20.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 184,334 shares of the company's stock after selling 47,213 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.08% of BioNTech worth $21,893,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BNTX. GAMMA Investing LLC grew its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock worth $41,000 after buying an additional 238 shares during the period. Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. raised its holdings in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after purchasing an additional 388 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC bought a new position in shares of BioNTech during the 2nd quarter worth about $206,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. The Goldman Sachs Group upgraded shares of BioNTech from a "neutral" rating to a "buy" rating and boosted their price target for the company from $90.00 to $137.00 in a research note on Friday, November 8th. TD Cowen dropped their price objective on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. Finally, BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a research report on Monday. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded up $2.88 during trading on Friday, hitting $121.72. 992,408 shares of the company were exchanged, compared to its average volume of 812,778. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The stock has a 50 day moving average of $113.84 and a 200 day moving average of $99.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market cap of $29.18 billion, a PE ratio of -59.09 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.73 EPS. As a group, equities research analysts predict that BioNTech SE will post -3.72 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.